Main content

Scientific publications generated within TransBioBC

 

Filip S, Zoidakis J, Vlahou A, Mischak H.
Advances in urinary proteome analysis and applications in systems biology.
Bioanalysis. 2014;6(19):2549-69. doi: 10.4155/bio.14.210.
 
Pontillo C, Filip S, Borràs DM, Mullen W, Vlahou A, Mischak H.
CE-MS-based proteomics in biomarker discovery and clinical application.
Proteomics Clin Appl. 2015 Apr;9(3-4):322-34. doi: 10.1002/prca.201400115. Epub 2015 Mar 24.
 
Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP. 
Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.
Am J Epidemiol. 2015 May 1;181(9):635-47. doi: 10.1093/aje/kwu462. Epub 2015 Mar 19.
 
Frantzi M, Latosonska A, Fluhe L, Hupe MC, Critselis E, Kramer MW, Merseburger AS, Mischak H, Vlahou A.
2015 Jun;12(6):317-330. doi: 10.1038/nrurol.2015.100. Epub 2015 May 26.
 
Frantzi M, Latosinska A, Merseburger AS, Mischak H.
Expert Rev Mol Diagn. 2015;15(12):1539-54.  Epub 2015 Oct 22.
 
Chatziharalambous D, Lygirou V, Latosinska A, Stravodimos K, Vlahou A, Jankowski V, Zoidakis J.
PLoS One. 2016 Feb 18;11(2):e0149471. doi: 10.1371/journal.pone.0149471. eCollection 2016.
 
Frantzi M, van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, Brand K, Dakna M, Roubelakis MG, Theodorescu D, Vlahou A, Mischak H, Anagnou NP.
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-   center Study.
Clinical Cancer Research. 2016 Mar 29.
 
Latosinska A, Makridakis M, Frantzi M, Borras DM, Janssen B, Mullen W, Zoidakis J, Merseburger AS,   Jankowski V, Mischak H, Vlahou A. 
Sci Rep. 2016 May 11;6:25619.
 
 
 
 
 
 
 

Other related scientific publications

Stalmach A, Husi H, Mosbahi K, Albalat A, Mullen W, Mischak H. Methods in capillary electrophoresis coupled to mass spectrometry for the identification of clinical proteomic/peptidomic biomarkers in biofluids. Methods Mol Biol. 2015;1243:187-205.

Pontillo C, Filip S, Borràs DM, Mullen W, Vlahou A, Mischak H. CE-MS based proteomics in biomarker discovery and clinical application. Proteomics Clin Appl. 2015 Jan 16. doi: 10.1002/prca.201400115

Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patietns initially treated with Bacullus-Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol. 2015 Jan;67(1):74-82

Bhat A, Heinzel A, Mayer B, Perco P, Mühlberger I, Husi H, Merseburger AS, Zoidakis J, Vlahou A, Schanstra JP, Mischak H, Jankowski V. Protein interactome of muscle invasive bladder cancer. PLoS One. 2015 Jan 8;10(1):e0116404

Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. Urol Oncol. 2014 Oct;32(7):1069-77

Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A. Consideration o nthe use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol. 2014 Oct;32(7):1061-8

Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y, Malats N. Inflammatory Biomarkers and Bladder Cancer Prognosis: A Systematic Review. Eur Urol. 2014 Aug 20. pii: S0302-2838(14)00685-X. doi: 10.1016/j.eururo.2014.07.033.

Mischak H, Vlahou A, Righetti PG, Calvete JJ. Putting value in biomarker research and reporting. J Proteomics. 2014 Jan 16;96:A1-3

Filip S, Zoidakis J, Vlahou A, Mischak H. Advances in urinary proteome analysis and applications in systems biology. Bioanalysis. 2014;6(19):2549-69

Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol. 2014 Jan 9.

Mermelekas G, Makridakis M, Koeck T, Vlahou A. Redox proteomics: from residue modifications to putative biomarker identification by gel- and LC-MS-based approaches. Expert Rev Proteomics. 2013 Dec;10(6):537-49

Latosinska A, Frantzi M, Vlahou A, Mischak H. Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer. Proteomics Clin Appl. 2013 Aug 23.

Albalat A, Stalmach A, Bitsika V, Siwy J, Schanstra JP, Petropoulos AD, Vlahou A, Jankowski J, Persson F, Rossing P, Jaskolla TW, Mischak H, Husi H. Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. Proteomics. 2013 Oct;13(20):2967-75.

Frantzi M, Zoidakis J, Papadopoulos T, Zürbig P, Katafigiotis I, Stravodimos K, Lazaris A, Giannopoulou I, Ploumidis A, Mischak H, Mullen W, Vlahou A. IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. J Proteome Res. 2013 Sep 6;12(9):3969-79.

Mischak H, Ioannidis JPA, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung H, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP and Vlahou A. Implementation of proteomic biomarkers: making it work. European Journal of Clinical Investigation, 2012; 42(9):1027-36

Zoidakis J, Makridakis M, Zerefos PG, Bitsika V, Esteban S, Frantzi M, Stravodimos K, Anagnou NP, Roubelakis MG, Sanchez-Carbayo M, Vlahou A
Profilin 1 is a potential biomarker for bladder cancer aggressiveness.
Mol Cell Proteomics 2012 11(4):M111.009449

Vlahou A. Back to the future in bladder cancer research. Expert Rev Proteomics. 2011; 8(3):295-7.

Makridakis M, Roubelakis MG, Bitsika V, Dimuccio V, Samiotaki M, Kossida S, Panayotou G, Coleman J, Candiano G, Anagnou NP, Vlahou A. Analysis of secreted proteins for the study of bladder cancer cell aggressiveness,
Journal of Proteome Research 2010; 9(6):3243-59

Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, Neuhaus J, Stolzenburg JU, Conaway MR, Mischak H, Theodorescu D. Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics.
Clin Cancer Res. 2009; 15 (15), 4935-4943.